Aardvark Therapeutics, Inc. 8-K

What Happened
Aardvark Therapeutics, Inc. (AARD) filed a Form 8-K on May 7, 2026 to report its results of operations and financial condition for the three months ended March 31, 2026. The company furnished a press release dated May 7, 2026 (Exhibit 99.1) that provides the quarterly financial results and business updates. The filing was signed by CEO Tien-Li Lee, M.D.

Key Details

• Filing date: May 7, 2026 (Form 8-K).
• Reporting period: Three months ended March 31, 2026 (Q1 2026).
• Exhibit: Press release dated May 7, 2026 furnished as Exhibit 99.1.
• Signed by: Tien-Li Lee, M.D., Chief Executive Officer.

Why It Matters
This 8-K formally notifies investors that Aardvark has released its quarterly results and related business updates; investors should read the attached press release for specific earnings, revenue, guidance, and operational details. Because the filing contains the company’s quarterly results, it can affect investor outlook, trading, and valuation depending on the numbers and management commentary disclosed in the press release.